Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.41 |
| ▸ | CDK7 | P50613 | 6/20 | 0.40 |
| ▸ | CCNH | P51946 | 6/20 | 0.40 |
| ▸ | MNAT1 | P51948 | 6/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 4/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | CCNK | O75909 | 3/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18986992 | 1.00 | USP30 (0.46) | USP30MCHR1ADRA2ANPY5RGRIN2B | |
| SCHEMBL19017746 | 0.86 | IDO1 (0.55) | USP30MCHR1ADRA2ANPY5RIDO1 | |
| SCHEMBL29908216 | 0.86 | IDO1 (0.55) | USP30MCHR1ADRA2ANPY5RIDO1 | |
| SCHEMBL28592475 | 0.86 | IDO1 (0.55) | USP30MCHR1ADRA2ANPY5RIDO1 | |
| SCHEMBL18987030 | 0.82 | USP30 (0.70) | USP30GRIN2BCYP11B2 | |
| SCHEMBL18987031 | 0.82 | USP30 (0.70) | USP30GRIN2BCYP11B2 | |
| SCHEMBL18571586 | 0.81 | MCHR1 (0.52) | USP30MCHR1ADRA2ANPY5RHCRTR1 | |
| SCHEMBL25398239 | 0.78 | USP30 (0.43) | USP30IDO1TDO2 | |
| SCHEMBL25401409 | 0.78 | USP30 (0.43) | USP30IDO1TDO2 | |
| SCHEMBL25398234 | 0.78 | USP30 (0.43) | USP30IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958833-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-16 | — | — | US | disclosed |
| EP-4122929-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| US-20210380562-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-11130748-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-28 | — | — | US | disclosed |
| US-20200172516-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| EP-3390391-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017103614-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380562-A1 | Novel Compounds | USP30, USP20, USP10 | USP30 1/4885MCHR1 3305/4885ADRA2A 3961/4885 |
| US-11130748-B2 | Compounds | USP30, USP20, USP10 | USP30 1/4885MCHR1 3569/4885ADRA2A 4141/4885 |
| US-20200172516-A1 | Novel Compounds | USP30, USP20, USP10 | USP30 1/4885MCHR1 3305/4885ADRA2A 3961/4885 |
| US-11958833-B2 | Compounds | USP30, USP20, USP10 | USP30 1/4885MCHR1 3569/4885ADRA2A 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.